From the FDA Drug Label
DOSAGE AND ADMINISTRATION General NOTE: CONTAINS BENZYL ALCOHOL (see PRECAUTIONS). IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT
The FDA drug label does not answer the question.
From the Research
Kenalog (triamcinolone acetonide) injections for interstitial cystitis typically range from 10 to 40 mg per treatment, with the most common dose being 40 mg diluted in 10-20 mL of sterile saline or lidocaine solution, as part of a comprehensive treatment approach to reduce inflammation and alleviate symptoms 1.
Key Considerations
- The medication is administered directly into the bladder wall via cystoscopy, targeting areas of inflammation and Hunner's lesions if present.
- Treatment intervals generally range from 3 to 6 months depending on symptom relief duration, though some patients may require more frequent administration initially.
- This steroid injection works by reducing inflammation in the bladder tissue, which helps decrease pain, urgency, and frequency associated with interstitial cystitis.
Potential Side Effects and Considerations
- Patients should be aware that potential side effects include temporary worsening of symptoms for 24-48 hours after injection, urinary tract infection risk, and systemic steroid effects if absorbed.
- The procedure is usually performed in an outpatient setting under local anesthesia or light sedation.
Comprehensive Treatment Approach
- Kenalog injections are typically used as part of a comprehensive treatment approach that may include oral medications, dietary modifications, and other bladder therapies.
- The diagnosis of Hunner-type interstitial cystitis or bladder pain syndrome requires cystoscopy to determine the presence or absence of Hunner lesions, and treatment should be tailored accordingly 1.